Does Aetna (CVS Health) Cover Testosterone Enanthate?

Aetna's Coverage Policy for Testosterone Enanthate

Aetna (CVS Health) classifies testosterone enanthate as a covered medication for the treatment of male hypogonadism when specific clinical criteria are met. Coverage extends across most commercial PPO and HMO plan designs, though individual employer-sponsored plans may impose additional restrictions or exclusions.

The core requirement is a confirmed diagnosis of hypogonadism. Aetna's clinical policy bulletins align with the Endocrine Society's 2018 clinical practice guidelines, which recommend testosterone therapy for men with symptomatic testosterone deficiency confirmed by at least two morning serum total testosterone measurements below 300 ng/dL. Aetna does not cover testosterone enanthate for age-related testosterone decline without documented clinical hypogonadism, for athletic performance, or for off-label weight loss.

Prescribers should be aware that Aetna acquired by CVS Health operates its pharmacy benefits through CVS Caremark, meaning formulary placement, step therapy edits, and prior authorization workflows all run through the CVS Caremark system. This matters because a prescription filled at a CVS pharmacy may process differently than one filled at an independent pharmacy depending on network tier status.

The American Urological Association's 2018 guidelines also support testosterone replacement for men with low testosterone confirmed by reliable assays, and Aetna references these guidelines in adjudicating coverage requests.

Formulary Tier and Cost

Testosterone enanthate sits on Aetna's preferred generic tier for most commercial formularies. That's good news for patients. Generic testosterone enanthate (200 mg/mL, typically supplied as a 5 mL vial) costs significantly less than branded alternatives.

On a standard Aetna commercial plan, patients can expect copays between $10 and $40 per month at preferred pharmacies. Plans with coinsurance structures instead of flat copays may charge 10% to 25% of the negotiated rate, which for a generic injectable testosterone product usually translates to $7 to $18 per fill. The FDA-approved labeling for testosterone enanthate specifies dosing of 50 to 400 mg every 2 to 4 weeks for replacement therapy, so monthly costs depend on the prescribed dose and injection frequency.

For patients without insurance or those facing a coverage gap, cash-pay prices average approximately $70 per month through discount programs like GoodRx or RxSaver. The manufacturer list price hovers around $120 per month, though actual out-of-pocket cost rarely reaches that figure for insured patients on a generic tier.

CVS Caremark's formulary lookup tool allows patients to verify their specific plan's tier placement before filling. Plans that use a closed formulary may restrict coverage to specific manufacturers of generic testosterone enanthate, so checking the formulary before the first fill avoids unexpected costs.

Prior Authorization Requirements

Aetna requires prior authorization for testosterone enanthate on most plan designs. The PA process involves moderate-to-high documentation requirements compared to other generic injectables.

To satisfy Aetna's PA criteria, the prescribing clinician must submit documentation showing: a confirmed diagnosis of primary or secondary hypogonadism (ICD-10 codes E29.1 or E23.0), at least two morning serum total testosterone levels below 300 ng/dL drawn on separate days, clinical symptoms consistent with testosterone deficiency (fatigue, decreased libido, erectile dysfunction, loss of muscle mass, or depressed mood), and the absence of contraindications such as untreated polycythemia, severe untreated sleep apnea, or active prostate or breast cancer.

The Endocrine Society guidelines specify that testosterone measurements should be obtained between 7:00 AM and 11:00 AM using a reliable assay, and Aetna mirrors this requirement. Labs drawn in the afternoon, when testosterone levels naturally dip, may not be accepted as valid documentation.

Standard PA requests are processed within 15 calendar days. Urgent requests receive a decision within 72 hours. Clinicians can submit PA requests through the CVS Caremark provider portal, by fax, or by phone. Electronic submission through the portal typically results in faster turnaround. If additional documentation is needed, Aetna sends a request to the prescriber, and the 15-day clock pauses until the information is received.

One practical consideration: Aetna may require periodic reauthorization, typically every 12 months. At reauthorization, the plan may request follow-up labs including total testosterone levels on therapy, hematocrit (to screen for polycythemia), and PSA. The T-Trials, a set of seven coordinated trials published in the New England Journal of Medicine enrolling 790 men aged 65 and older with low testosterone, demonstrated that testosterone treatment increased testosterone levels to the mid-normal range and improved sexual function, physical function, and vitality. These trial results inform the clinical benchmarks Aetna uses when evaluating whether ongoing therapy remains medically necessary.

Step Therapy Requirements

Some Aetna plans enforce step therapy before approving testosterone enanthate. This means the plan requires the patient to try a preferred first-line therapy before covering the requested drug.

For testosterone replacement, step therapy on Aetna plans typically requires documentation that the patient has tried or has a clinical reason to avoid topical testosterone (gels such as generic testosterone gel 1% or AndroGel). Topical formulations often sit on a lower formulary tier or carry fewer restrictions on some plan designs. If a patient has tried and failed topical testosterone, experienced skin reactions, has household members at risk of transfer exposure (children or pregnant partners), or has a documented clinical reason favoring injections, the step therapy edit can be overridden.

The prescriber submits this information as part of the PA request. A simple statement such as "patient has young children in the household, transfer risk with topical formulation" or "patient tried topical testosterone gel for 90 days without adequate response, trough level remained at 280 ng/dL" is usually sufficient to bypass the step therapy requirement.

Not all Aetna plans impose step therapy for testosterone enanthate. Employer-sponsored plans can customize their formulary edits, so some plans approve injectable testosterone without requiring a topical trial first. Patients should call the number on the back of their Aetna ID card to confirm whether their specific plan includes a step therapy requirement.

A 2020 retrospective analysis of commercial claims data found that approximately 30% of men initiating testosterone therapy switched formulations within the first year, most commonly from topical to injectable, citing convenience and cost as primary reasons (Baillargeon et al., 2015). This pattern suggests that step therapy edits requiring a topical trial may delay but usually do not permanently block access to injectable testosterone enanthate.

How to Appeal a Denied Testosterone Enanthate Claim

If Aetna denies coverage for testosterone enanthate, the denial letter will include the specific clinical rationale and instructions for filing an appeal. The appeal process follows a defined pathway.

First-level internal appeal. The patient or prescriber has 180 days from the denial date to file an internal appeal. The appeal should include a letter from the prescribing physician explaining why testosterone enanthate is medically necessary, relevant lab results (two morning testosterone levels below 300 ng/dL), documentation of symptoms, and any relevant clinical guidelines supporting the request. Citing the Endocrine Society's 2018 guidelines and the AUA's 2018 testosterone therapy evaluation and management guidelines strengthens the appeal. Aetna must respond to internal appeals within 30 calendar days for standard requests or 72 hours for urgent/expedited appeals.

External review. If the internal appeal is denied, patients can request an independent external review through their state's insurance department or through Aetna's designated independent review organization. External reviews are conducted by physicians who were not involved in the original denial. The external reviewer's decision is binding on Aetna.

Common reasons for denial include: insufficient documentation (only one testosterone level submitted instead of two), labs drawn outside the recommended morning window, lack of documented symptoms, or failure to complete required step therapy. Addressing these specific gaps in the appeal letter significantly improves the chance of reversal.

According to data from the Kaiser Family Foundation, internal appeals for prescription drug denials are overturned approximately 40% to 60% of the time when supported by adequate clinical documentation. For testosterone therapy specifically, denials most often result from administrative gaps rather than true clinical ineligibility.

Testosterone Enanthate vs. Other Covered Formulations on Aetna

Aetna's formulary includes several testosterone replacement options beyond testosterone enanthate. Understanding relative coverage helps patients and prescribers choose the most accessible option.

Testosterone cypionate, the other widely used injectable ester, carries nearly identical coverage terms on Aetna plans. Both are generic, both sit on preferred tiers, and both require PA. The clinical difference between the two esters is minimal. A pharmacokinetic comparison shows that testosterone enanthate has a half-life of approximately 4.5 days while testosterone cypionate has a half-life of approximately 8 days, though in practice both are dosed every 1 to 2 weeks for replacement therapy (Nieschlag & Nieschlag, 2019).

Topical testosterone gel (generic 1% and 1.62% formulations) may be covered with fewer restrictions on some Aetna plans, particularly those with step therapy edits favoring topicals. AndroGel and Testim, the branded gel products, typically sit on higher formulary tiers (Tier 3 or non-preferred brand) and carry higher copays.

Testosterone undecanoate (Aveed), the long-acting injectable administered every 10 weeks after a loading phase, is covered by Aetna but classified as a specialty medication. It requires specialty pharmacy dispensing, carries a higher cost (approximately $1,500 per injection without insurance), and must be administered in a healthcare setting with a 30-minute post-injection observation period per FDA REMS requirements. For most patients, generic testosterone enanthate or cypionate offers a more practical and cost-effective option.

Nasal testosterone (Natesto) and oral testosterone undecanoate (Jatenzo) are also available but typically sit on non-preferred or specialty tiers with significantly higher out-of-pocket costs on Aetna plans.

Using Manufacturer Savings Cards with Aetna

Manufacturer copay savings cards and discount programs interact with Aetna coverage in specific ways that patients should understand before relying on them.

For generic testosterone enanthate, manufacturer savings cards are generally not available because the product is off-patent and manufactured by multiple generic drug companies. Savings cards are typically offered by brand-name manufacturers to offset higher copays on branded products.

However, patients with Aetna who face unexpectedly high copays for generic testosterone enanthate have several options. GoodRx, RxSaver, and similar discount programs can sometimes offer prices below the insurance copay, particularly at independent pharmacies. In these cases, patients can ask the pharmacist to run the prescription as a cash-pay claim using the discount card instead of billing insurance. This does not count toward the plan's deductible or out-of-pocket maximum, so patients should weigh the trade-off.

For branded testosterone products (AndroGel, Axiron, Testim, Aveed, Jatenzo), manufacturer savings cards may reduce copays to as low as $0 to $25 per fill. Aetna commercial plans generally allow copay cards to be applied at the point of sale. Aetna Medicare Advantage plans, however, prohibit the use of manufacturer copay cards per CMS regulations.

Patients enrolled in Aetna plans through government programs (Medicare, Medicaid, TRICARE, or VA) cannot use manufacturer copay assistance due to federal anti-kickback statute requirements. The patient assistance programs offered directly by some manufacturers (distinct from copay cards) may still be available to qualifying low-income patients regardless of plan type.

Monitoring Requirements That Affect Ongoing Coverage

Aetna's reauthorization criteria for testosterone enanthate require periodic lab monitoring, which directly affects continued coverage approval. Missing these labs can trigger a coverage lapse at the annual reauthorization point.

The Endocrine Society recommends checking serum testosterone levels 3 to 6 months after initiating therapy, then annually. The target trough level (drawn just before the next injection) should fall within the normal range of 300 to 1 to 000 ng/dL. Aetna's reauthorization criteria generally require documentation that the patient's testosterone level has reached the therapeutic range.

Hematocrit monitoring is also required. Testosterone therapy increases erythropoiesis, and hematocrit levels above 54% necessitate dose reduction or temporary discontinuation. The T-Trials found that testosterone-treated men experienced a mean hematocrit increase of 2.5 percentage points compared to placebo over 12 months (Snyder et al., NEJM 2016). Aetna may request hematocrit values at reauthorization to verify the prescriber is monitoring for this known risk.

PSA screening is recommended before initiating testosterone therapy and at 3 to 6 months and 12 months after starting, per the AUA guidelines. A PSA increase of greater than 1.4 ng/mL within any 12-month period warrants urological evaluation. While Aetna does not universally require PSA at reauthorization, some plan designs include it as a condition for continued approval.

Bone mineral density testing may be recommended for men with hypogonadism who had low bone density at baseline. A study published in the Journal of Clinical Endocrinology & Metabolism as part of the T-Trials showed that testosterone treatment for 12 months significantly increased volumetric bone mineral density of the spine by 7.5% compared to placebo in older men with low testosterone (Snyder et al., 2017).

Patients on testosterone enanthate through Aetna should keep copies of all lab results and ensure their prescriber submits updated documentation before the reauthorization deadline, typically 30 days before the current authorization expires.